This move is archived. Current quotes and coverage live on the stock page.
Get TLT alerts:
Theralase Technologies Inc. is seeing a nice boost in its stock performance, closing up 1.96% in the latest trading session.
In this session, Theralase Technologies Inc. (TLT.V) saw its stock price rise by 1.96%, closing at CA$0.26. This increase shows a positive sentiment among investors, thanks to ongoing developments in the company's clinical studies and financial initiatives.
Advertisement
Theralase Technologies Inc.
TLT.V
TLT.V
Theralase Technologies Inc.
WealthAwesomeMarket cap
$54.70M
52W high
$0.41
52W low
$0.15
1W change
+0.00%
Beta
0.59
Analyst Price Targets
Based on analyst covering TLT
Wall Street analysts forecast TLT stock price to rise 278.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.70
+278.4% Upside
Current Price
C$0.18
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TLT's historical volatility
30-Day Vol
87.1%
Annualized
90-Day Vol
100.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.15
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.17 | C$0.13 โ C$0.24 |
| 60 trading days | C$0.16 | C$0.11 โ C$0.25 |
| 90 trading days | C$0.15 | C$0.09 โ C$0.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Even though the market cap is still modest at CA$78.35 million, Theralase's recent stock performance might indicate growing investor confidence as it continues to advance its clinical programs.
Theralase Technologies Inc. Stock Climbs 1.96%
The stock's closing price of CA$0.26 reflects a growing interest in Theralase's innovative therapies.
Bull case
Theralase's ongoing clinical studies and recent financial initiatives, like the successful completion of a C$4.8 million offering, strengthen its potential for future growth and market interest.
Bear case
Despite the positive movement, Theralase operates in a highly competitive biotech sector. Its lack of profitability and dividend yield might turn off risk-averse investors.
Recent Performance Overview
Advertisement
Theralase Technologies Inc. has had a positive trading session, with its stock closing up 1.96% at CA$0.26. This upward movement may signal growing investor confidence as the company continues to advance its clinical studies.
Factors Contributing to Stock Performance
The recent completion of a C$4.8 million financing round has given Theralase additional resources to support its clinical initiatives. This financial backing, along with ongoing developments in its research programs, may be driving the positive sentiment around the stock.
Looking Ahead
As Theralase Technologies Inc. navigates the complexities of the biotech landscape, its ability to deliver on clinical promises will be crucial. Investors should watch for upcoming announcements and financial results that could further influence stock performance. For more insights, check out our detailed analysis on Theralase Technologies.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
